Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tunis Presses NIH To Share ICD Study Findings; Dollens Claims Data Irrelevant

This article was originally published in The Gray Sheet

Executive Summary

CMS will contact the National Heart, Lung & Blood Institute within the next two weeks to try to determine why SCD-HeFT study patients who met the MADIT-II trial criteria were not switched to the active ICD treatment arm

You may also be interested in...



Scully’s Successor Awaited By Device Reps: Will Improved Access Continue?

Retaining access to top-level CMS officials is a primary objective of device stakeholders following the imminent departure of Administrator Tom Scully

Scully’s Successor Awaited By Device Reps: Will Improved Access Continue?

Retaining access to top-level CMS officials is a primary objective of device stakeholders following the imminent departure of Administrator Tom Scully

CMS To Meet With NASPE/HRS, Manufacturers To Review ICD Decision Process

Guidant maintains that its MADIT-II trial ethically could not have been extended to provide more evidence of the long-term benefits of ICDs for the entire study population

Related Content

UsernamePublicRestriction

Register

MT018136

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel